Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray,Jacques Ferlay,Isabelle Soerjomataram,Rebecca L. Siegel,Lindsey A. Torre,Ahmedin Jemal +5 more
Reads0
Chats0
TLDR
A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.Abstract:
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions There will be an estimated 181 million new cancer cases (170 million excluding nonmelanoma skin cancer) and 96 million cancer deaths (95 million excluding nonmelanoma skin cancer) in 2018 In both sexes combined, lung cancer is the most commonly diagnosed cancer (116% of the total cases) and the leading cause of cancer death (184% of the total cancer deaths), closely followed by female breast cancer (116%), prostate cancer (71%), and colorectal cancer (61%) for incidence and colorectal cancer (92%), stomach cancer (82%), and liver cancer (82%) for mortality Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality) Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts CA: A Cancer Journal for Clinicians 2018;0:1-31 © 2018 American Cancer Societyread more
Citations
More filters
Journal ArticleDOI
Burden of Gastric Cancer.
TL;DR: This article discusses the descriptive epidemiology of gastric cancer, including its incidence, mortality, survival, and secular trends, and combines a synthesis of published studies with an analysis of data from the International Agency for Research on Cancer (IARC) GLOBOCAN project to describe the global burden.
Journal ArticleDOI
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn,Masafumi Ikeda,Andrew X. Zhu,Max W. Sung,Ari David Baron,Masatoshi Kudo,Takuji Okusaka,Masahiro Kobayashi,Hiromitsu Kumada,Shuichi Kaneko,Marc Pracht,Konstantin Mamontov,Tim Meyer,Tomoki Kubota,Corina E. Dutcus,Kenichi Saito,Abby B. Siegel,Leonid Dubrovsky,Kalgi Mody,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC, and toxicities were manageable, with no unexpected safety signals.
Journal ArticleDOI
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Thomas Yau,Yoon-Koo Kang,Tae-You Kim,Anthony B. El-Khoueiry,Armando Santoro,Bruno Sangro,Ignacio Melero,Masatoshi Kudo,Ming Mo Hou,Ana Matilla,Francesco Tovoli,Jennifer J. Knox,Aiwu Ruth He,Bassel F. El-Rayes,Mirelis Acosta-Rivera,Ho Yeong Lim,Jaclyn Neely,Yun Shen,Tami Wisniewski,Jeffrey Anderson,Chiun Hsu +20 more
TL;DR: The manageable safety profile and promising response rates observed in this study support further investigation of nivolumab plus ipilimumab as a treatment option for this patient population.
Journal ArticleDOI
Revised FIGO staging for carcinoma of the cervix uteri
Neerja Bhatla,Jonathan S. Berek,Mauricio Cuello Fredes,Lynette Denny,Seija Grénman,Kanishka Karunaratne,Sean Kehoe,Ikuo Konishi,Alexander B. Olawaiye,Jaime Prat,Rengaswamy Sankaranarayanan,Rengaswamy Sankaranarayanan,James Brierley,David G. Mutch,Denis Querleu,David Cibula,Michael A. Quinn,Hennie Botha,Lax Sigurd,Laurel W. Rice,Hee-Sug Ryu,Hextan Y.S. Ngan,Johanna Mäenpää,Andri Andrijono,Gatot Purwoto,Amita Maheshwari,Uttam D. Bafna,Marie Plante,Jayashree Natarajan +28 more
TL;DR: To revise FIGO staging of carcinoma of the cervix uteri, allowing incorporation of imaging and/or pathological findings, and clinical assessment of tumor size and disease extent.
Journal ArticleDOI
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications
Sunny H. Wong,Jun Yu +1 more
TL;DR: The role of microorganisms in colorectal carcinogenesis, and the potential clinical translation of the gut microbiota as a biomarker for CRC diagnosis and prognosis are described, and as an approach for disease prevention and to improve therapy are described.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Global cancer statistics, 2012
Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet-Tieulent,Ahmedin Jemal +5 more
TL;DR: A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.
Journal ArticleDOI
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Book
Cancer Incidence in Five Continents
Freddie Bray,J. Ferlay,Mathieu Laversanne,David H. Brewster,C. Gombe Mbalawa,B. Kohler,Marion Piñeros,Eva Steliarova-Foucher,Rajaraman Swaminathan,Sebastien Antoni,Isabelle Soerjomataram,David Forman +11 more
TL;DR: The aim of this study was to establish a database of histological groups and to provide a level of consistency and quality of data that could be applied in the design of future registries.